**Name of journal: World Journal of Gastrointestinal Pharmacology and Therapeutics**

**ESPS Manuscript NO: 2580**

**Columns: BRIEF ARTICLE**

**Association of *ITPA* polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy**

**Fujino T *et al*.** *ITPA* polymorphism and antiviral therapy

Tatsuya Fujino, Yoko Aoyagi, Mariko Takahashi, Ryoko Yada, Naoko Yamamoto, Yuki Ohishi, Akihiko Nishiura, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuizumi, Manabu Nakashima, Masaki Kato, Kazuhiro Kotoh, Makoto Nakamuta, Munechika Enjoji

**Tatsuya Fujino,** Laboratory for Clinical Investigation, National Hospital Organization Nagasaki Medical Center, Ohmura, Nagasaki 856-8562, Japan

**Yoko Aoyagi, MarikoTakahashi, Ryoko Yada, Naoko Yamamoto, Yuki Ohishi, Akihiko Nishiura, Motoyuki Kohjima, Tsuyoshi Yoshimoto, Kunitaka Fukuizumi, Makoto Nakamuta, Munechika Enjoji,** Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Fukuoka 814-0180, Japan

**Manabu Nakashima, Munechika Enjoji,** Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka 814-0180, Japan

**Masaki Kato, Kazuhiro Kotoh,** Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 814-0180, Japan

**Author contributions:** Fujino T, Nakamuta M, and Enjoji M designed the research; Fujino T, Kohjima M, Yoshimoto T, Fukuizumi K, Kato M, and Kotoh K performed the research; Fujino T, Aoyagi Y,Takahashi M, Yada R, Yamamoto N, Ohishi Y, and Nishiura A analyzed the data; Fujino T and Enjoji M wrote the paper; Nakamuta M and Nakashima M reviewed it.

**Supported by** the Research Program of Intractable Disease provided by the Ministry of Health, Labor and Welfare of Japan, and a Grant-in-Aid for Clinical Research from the National Hospital Organization of Japan

**Correspondence to:** **Munechika Enjoji, MD, PhD,** Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. enjoji@adm.fukuoka-u.ac.jp

**Telephone:** +81-92-8716631 **Fax:** +81-92-8630389

**Received:** March 1, 2013 **Revised:** May 16, 2013

**Accepted:** May 18, 2013

**Published online:**

**Abstract**

**AIM:** To analyzed the association between inosine triphosphatase (*ITPA*) (rs1127354) genotypes and sustained virological r May 18, 2013

esponse (SVR) rates in peginterferon (Peg-IFN) α + ribavirin (RBV) treatment.

**METHODS:** Patients who underwent Peg-IFNα + RBV combination therapy were enrolled (*n =* 120) and they had no history of other IFN-based treatments. Variation in hemoglobin levels during therapy, cumulative reduction of RBV dose, frequency of treatment withdrawal, and SVR rates were investigated in each *ITPA* genotype.

**RESULTS:** In patients with *ITPA* CC genotype, hemoglobin decline was significantly greater and the percentage of patients in whom total RBV dose was <60% of standard and/or treatment was withdrawn was significantly higher compared with CA/AA genotype. However, SVR rates were equivalent between CC and CA/AA genotypes, and within a subset of patients with IL28B (rs8099917) TT genotype, SVR rates tended to be higher in patients with *ITPA* CC genotype, although the difference was not significant.

**CONCLUSION:** *ITPA* CC genotype was a disadvantageous factor for Peg-IFNα + RBV treatment in relation to completion rates and RBV dose. However, CC genotype was not inferior to CA/AA genotype for SVR rates. When full-length treatment is accomplished, it is plausible that more SVR is achieved in patients with *ITPA* CC variant, especially in a background of IL28B TT genotype.

© 2013 Baishideng. All rights reserved.

**Key words:** Chronic hepatitis C; Interleukin 28B; Inosine triphosphatase; Peginterferon; Ribavirin

**Core TIP:** Inosine triphosphatase (*ITPA*) polymorphism at rs1127354 is significantly associated with hemoglobin decline and reduction of ribavirin (RBV) during peginterferon (Peg-IFN)α + RBV therapy. However, the effect of the *ITPA* gene single-nucleotide polymorphism on treatment outcome is still unclear. In this study, *ITPA* CC genotype (rs1127354) was not inferior to CA/AA genotype for SVR rates although CC genotype was a disadvantageous factor for the treatment in relation to completion rates and RBV dose. When full-length treatment is accomplished, the SVR rate tended to be higher in patients with the CC genotype, especially in a subset of patients with the favorable TT genotype (rs8099917) of IL28B.

Fujino T, Aoyagi Y, Takahashi M, Yada R, Yamamoto N, Ohishi Y, Nishiura A, Kohjima M, Yoshimoto T, Fukuizumi K, Nakashima M, Kato M, Kotoh K, Nakamuta M, Enjoji M. Association of *ITPA* polymorphism with outcomes of peginterferon-α plus ribavirin combination therapy.

**Available from: URL:**

**DOI:**

**INTRODUCTION**

Hepatitis C virus (HCV) genotype 1b accounts for around 70% of chronic hepatitis C in Japan[1,2]. A sustained virological response (SVR) in eliminating HCV RNA by peginterferon (Peg-IFN)α + ribavirin (RBV) combination therapy is attained in 40–50% of individuals with HCV-1b[3-5]. Triple therapy using Peg-IFNα + RBV + telaprevir is anticipated to be effective for SVR in approximately 75% of patients with HCV-1b[6-8]. It is known that polymorphisms located upstream of the IL28B gene, encoding for λ or type III interferon (IFN-λ), are major predictors of SVR in the Peg-IFNα-based combination therapies[9-12]. Two single-nucleotide polymorphisms (SNPs), rs8099917 TT genotype and rs12979860 CC genotype, have been independently associated with a higher rate of SVR following Peg-IFNα-based combination therapies in individuals with HCV-1b infection. IFN-λ is believed to upregulate the JAK–STAT (Janus kinase–signal transducer and activator of transcription) pathway through interaction with a cellular transmembrane receptor, resulting in antiviral activity. In Japanese individuals, strong linkage disequilibrium is recognized between the two IL28B SNPs, rs8099917 and rs12979860, and 99% coincidence has been reported[13].

The most important adverse events of Peg-IFNα-based combination therapies include RBV-induced hemolytic anemia, which is severe enough to require dose reduction of RBV in 10%–20% of patients, and which may affect overall efficacy[3]. RBV-induced ATP depletion in red blood cells is believed to be a primary mechanism for RBV-induced hemolytic anemia. A genome-wide association study has shown a strong association between SNPs of the inosine triphosphatase (*ITPA*) gene in chromosome 20 and RBV-induced anemia in patients infected with HCV-1b[14]. Two functional SNPs, a missense variant in exon 2 (rs1127354) and a splicing altering variant in intron 2 (rs7270101), independently reduce the expression of *ITPA*, leading to inosine deficiency and protection against RBV-induced ATP depletion[15-18]. Accordingly, the protective genotypes, rs1127354 CA and AA as well as rs7270101 AC and CC, are associated with decreased *ITPA* activity, which confers protection against RBV-related ATP depletion and hemolytic anemia. The Japanese have the AA genotype exclusively at rs7270101, therefore the CC genotype at rs1127354 is a major predictor of RBV-induced anemia during antiviral combination therapy in Japanese patients infected with HCV-1b[18,19].

However, it is controversial whether *ITPA* (rs1127354) CC genotype, which induces heavier hemoglobin decline, affects therapeutic outcomes. From the standpoint of health economics, it is important to examine the significance of factors predicting viral response to antiviral treatments and therapeutic outcomes. In this study, Japanese patients infected with HCV-1b, who had experienced Peg-IFNα + RBV combination therapy, were retrospectively analyzed. Patients were divided into groups according to genotyping of *ITPA* rs1127354 and IL28B rs8099917. Our primary analysis was focused on the quantitative change from baseline in hemoglobin levels and platelet counts, cumulative reduction of RBV dose, frequency of treatment withdrawal, and estimation of treatment outcome.

**MATERIALS AND METHODS**

***Study patients***

This retrospective cohort study was performed in 120 patients with chronic HCV-1b infection who were treated with Peg-IFNα + RBV combination therapy at Kyushu Medical Center Hospital between January 2007 and December 2009. The patients met the following inclusion and exclusion criteria. Inclusion criteria were: (1) baseline serum HCV RNA levels >5.0 log IU/mL; and (2) Japanese patients aged 20–65 years at study entry. Exclusion criteria were: (1) decompensated liver cirrhosis; (2) serum hepatitis B surface antigen; (3) hepatocellular carcinoma or its history; (4) autoimmune hepatitis, alcoholic liver disease, hemochromatosis, or chronic liver disease other than chronic hepatitis C; (5) chronic renal disease or creatinine clearance < 50 mL/min at baseline; (6) hemoglobin < 12 g/dL, neutrophil < 1500/μL or platelets < 100000/μL at baseline; and (7) history of receiving IFN-based treatment. All patients gave consent for analysis of SNPs in *ITPA* and IL28B genes. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and was approved by the Ethics Committee of Kyushu Medical Center. Written informed consent was obtained from each patient.

***Antiviral treatment***

Peg-IFNα2b (1.5 μg/kg) or Peg-IFNα2a (180 μg) was injected subcutaneously once weekly. RBV (600–1000 mg daily) was administered after breakfast and dinner. The RBV dose was adjusted by body weight: 600 mg for < 60 kg; 800 mg for 60–80 kg; and 1000 mg for > 80 kg. As a standard combination therapy, Peg-IFNα and RBV were continued for 48 wk. Treatment duration was extended up to 72 wk in some patients in whom HCV RNA first became undetectable after week 12 but before week 48. SVR was defined as undetectable serum HCV RNA for 24 wk after treatment completion. Rapid virological response (RVR) and early virological response (EVR) were defined as undetectable serum HCV RNA at 4 wk and 12 wk of Peg-IFNα + RBV treatment, respectively. The RBV dose was reduced by 200 mg in patients receiving 600 or 800 mg (by 400 mg in those receiving 1000 mg) when hemoglobin decreased to < 12 g/dL, and by another 200 mg when it was < 10 g/dL. RBV was withdrawn or stopped temporarily when hemoglobin levels decreased to < 8.5 g/dL. Dose of Peg-IFNα2b (or Peg-IFNα2a) was reduced by 50% when the leukocyte count decreased to < 1500/μL, neutrophil count to < 750/μL, or platelet count to <80000/μL; Peg-IFNα2b or Peg-IFNα2a was withdrawn when the above measures were decreased to < 1000/μL, < 500/μL, or < 50000 /μL, respectively.

***Laboratory data***

Hematological, biochemical, and virological parameters were determined by the clinical laboratory at Kyushu Medical Center. Serum HCV RNA concentrations were determined by the COBAS TaqMan PCR HCV test (Roche Diagnostics, Tokyo, Japan). Genotyping for the *IL28B* (rs8099917) and *ITPA* (rs1127354) polymorphisms was performed by TaqMan SNP Genotyping Assays (Applied Biosystems, Branchburg, NJ, United States) that apply a polymerase chain reaction (PCR)-based restriction fragment length polymorphism assay.

***Statistical analysis***

Statistical analysis was performed using JMP software (SAS Institute Inc., Cary, NC, USA). Differences between categorical variables were analyzed using Fisher’s exact test or 2 test. Mann–Whitney *U* test was used for continuous variables. Multivariate analysis was used to identify factors independently associated with the achievement of SVR. The OR and 95%CI were also calculated. *P* < 0.05 was considered to be statistically significant.

**RESULTS**

***Association between ITPA deficiency and hemoglobin decline***

Baseline characteristics of 120 enrolled patients are shown in Table 1. The study population included 83 patients with major (CC) genotype and 37 patients with minor (CA/AA) genotype of *ITPA* at rs1127354. Within listed items, no significant difference was seen between *ITPA* CC and CA/AA groups. Chronological variation of hemoglobin levels and platelet count during Peg-IFNα + RBV therapy is shown in Figure 1. As reported previously, hemoglobin decline was obvious in patients with *ITPA* CC genotype (rs1127354) and a significant difference was seen at week 1, 2, 4, 12, and 24 (Figure 1A), meaning that *ITPA* deficiency due to CA/CC genotype was associated with slower hemoglobin decline early in treatment. The greatest difference in mean hemoglobin reduction was found at week 4, while platelet reduction was temporally heavier in patients with *ITPA* CA/AA genotype at week 2 and 4 (Figure 1B). Leukocyte and neutrophil counts were equivalent between *ITPA* genotype CC and CA/AA groups during treatment (data not shown).

***Treatment outcome in each genotype of ITPA***

As a result of hepatocellular carcinoma, therapeutic inefficiency, or adverse events, such as depression, appetite loss, easy fatigability, retinal hemorrhage, and hemolytic anemia, Peg-IFNα + RBV therapy was discontinued in 18 patients with *ITPA* CC genotype (21.7%) and six patients with CA/AA genotype (16.2%). Moreover, serious reduction of RBV administration (< 60% of scheduled total dose) was compelled in significantly more patients with CC genotype compared with the CA/AA genotype. The percentage of patients receiving < 60% total RBV dose, including patients with treatment interruption/withdrawal, was significantly higher for the CC genotype (37.3% *vs* 21.6%, *P* < 0.05). To investigate the influence of dose reduction of Peg-IFN on treatment outcome, we also analyzed the dose of Peg-IFN administered for each rs1127354 genotype, and > 70% of the expected total dose was administered to all patients with treatment completion (data not shown). SVR rates were analyzed according to the total RBV dose and *ITPA* genotype (Table 2). In the whole population, SVR rates were higher in *ITPA* genotype CC than CA/AA genotype (44.6% *vs* 40.5%), although the difference was not significant. SVR rates tended to be higher for the CC genotype than the CA/AA genotype in patients with > 60% total RBV dose (58.5% *vs* 48.3%) or < 60% total RBV dose (20.0% *vs* 12.5%), but there were no significant differences between the *ITPA* genotypes.

SVR, RVR and EVR rates were determined for *IL28B* (rs8099917) and *ITPA* (rs1127354) genotypes (Table 3). In a subset of patients with IL28B TT genotype, RVR, RVR + EVR, and SVR showed higher rates in patients with *ITPA* CC genotype compared with CA/AA genotype, although the difference was not significant. In a subset of patients with *IL28B* TG/GG genotype, SVR rates were equivalent between CC and CA/AA genotypes.

When background of SVR and non-SVR patients was compared, there was a significant difference in age, HCV RNA concentrations, platelet counts, staging, and IL28 SNPs, but not in *ITPA* SNPs (Table 4). Table 5 shows the result of multivariate analysis for predictive factors associated with SVR. The multivariate analysis proved that viral load (HCV RNA < 6.0 log IU/mL) and *IL28B* TT (rs8099917) were independent factors for SVR.

**DISCUSSION**

It has been shown that the *SNP* (rs8099917) in the *IL28B* gene is strongly associated with response to IFN-based therapy for chronic HCV-1b infection, and the *SNP* (rs1127354) in the *ITPA* gene predicts RBV-induced anemia in the Japanese population[19-23]. In this study, patients with *ITPA* (rs1127354) genotype CC showed a higher degree of hemoglobin reduction in response to Peg-IFNα + RBV treatment at week 1, 2, 4, 12 and 24 compared with those with the CA/AA genotype (Figure 1A). The greatest difference in mean hemoglobin reduction was found at week 4. These findings confirmed the reported evidence that *ITPA* deficiency (rs1127354 CA/AA variants) renders protection against the development of RBV-induced hemoglobin decline in Japanese patients infected with HCV-1b[20-23]. The exact mechanism by which *ITPA* deficiency protects against RBV-induced hemolysis has yet to be resolved. One postulated mechanism for the development of anemia is the accumulation of triphosphorylated RBV in erythrocytes, causing eventual oxidative damage to erythrocyte membranes, and *ITPA* deficiency may confer protection against RBV-induced ATP reduction by substituting for erythrocyte GTP, which is depleted by RBV in the biosynthesis of ATP[24-26].

Thrombocytopenia, which leads to poor treatment efficacy because of the initial or early dose reduction of Peg-IFNα, is one of the critical adverse events caused by IFN-based antiviral therapy. A previous study has reported that the *ITPA* (rs1127354) CA/AA genotype is independently associated with a greater reduction in platelet count as well as protection against the reduction in hemoglobin, whereas patients with the CC genotype have significantly less reduction in mean platelet count[27]. We also evaluated whether genetic variants in the *ITPA* gene were associated with IFN-induced thrombocytopenia. In this study, CC genotype showed lesser trend of reduction at week 2 and 4 compared with CA/AA genotype (Figure 1B). The result may support the association of *ITPA* gene *SNP* (rs1127354) with platelet decline in response to Peg-IFNα + RBV treatment.

Hemoglobin reduction often necessitates dose reduction of RBV and premature withdrawal from therapy, therefore the *ITPA* (rs1127354) genotype CC may be considered as a disadvantageous factor for Peg-IFNα + RBV treatment. However, although *ITPA* polymorphisms are significantly associated with RBV-induced anemia, their effect on therapeutic outcome is unclear. Some studies have shown no association[14,28-31], and others have reported a possible association with treatment outcomes in chronic hepatitis C patients[21,22]. In the present study, although there was no significant association between *ITPA* polymorphisms and treatment outcome, there was a trend towards higher SVR rates in patients with *ITPA* CC genotype, which seemed to contradict previous studies[21,22,28-31]. The different outcome among the institutes may be due to the difference of inclusion and/or exclusion criteria. In this study, the relationship between IL28B and *ITPA* variants were additionally analyzed on treatment outcome. When analyzed in the patients available for treatment outcome, all patients were administered > 70% of the scheduled total Peg-IFNα dose, but the incidence of RBV dose reduction (< 60% of the scheduled dose) and withdrawal was significantly higher in patients with the rs1127354 genotype CC. However, the rate of SVR tended to be higher in patients with the CC genotype, especially in a subset of patients with the favorable TT genotype at rs8099917 of *IL28B*, although the difference was not significant between the CC and CA/AA genotypes (Tables 2 and 3). Independent favorable predictors for SVR identified in multivariate analysis were low viral load (HCV RNA <6.0 log IU/mL) and TT genotype at rs8099917 of *IL28B*, but not CC genotype at rs1127354 of *ITPA* (Table 5).

There were several limitations to this study. (1) Because of the small sample size which may have contributed to the loss of significance observed or some statistical errors, this study may be ranked at preliminary statu; (2) Because of the retrospective nature of the study, enrolled patients may not represent the standard Japanese population infected with HCV; (3) Several other significant SNPs, which have been detected in *ITPA* as well as *IL28B*, may have influenced and distorted the results; and (4) Mutations in other genes and non-genetic factors that may affect response to antiviral therapy against chronic hepatitis C were not determined.

In conclusion, the SVR rates tended to be higher in patients with the CC genotype than the CA/AA genotype, especially in a subset of patients with *IL28B* (rs8099917) TT genotype, despite a higher rate of RBV dose reduction and treatment withdrawal. Multivariate analysis identified *IL28B* *SNP* (rs8099917) and HCV RNA as independent predictors of SVR. It is plausible that, in a background of *IL28B* (rs8099917) TT genotype, more SVR is achieved in patients with *ITPA* CC variant when full-length (duration of 48 or 72 wk) treatment is accomplished. These findings indicate that *ITPA* (rs1127354) CC genotype is by no means inferior to the CA/AA genotype for viral response to Peg-IFN + RBV combination therapy.

**COMMENTS**

***Background***

A single-nucleotide polymorphism (SNP) at rs1127354 of the inosine triphosphatase (ITPA) gene is associated with hemoglobin decline during peginterferon (Peg-IFN) + ribavirin (RBV) combination therapy in patients with HCV infection. However, the effect of the ITPA gene SNP on treatment outcome has not been fully elucidated. Authors analyzed the association between ITPA (rs1127354) genotypes and sustained virological response (SVR) rates in Peg-IFNα + RBV treatment.

***Research frontiers***

ITPA CC genotype was a disadvantageous factor for Peg-IFNα + RBV treatment in relation to completion rates and RBV dose. However, CC genotype was not inferior to CA/AA genotype for SVR rates. When full-length treatment is accomplished, it is plausible that more SVR is achieved in patients with ITPA CC variant, especially in a background of IL28B TT genotype.

***Innovations and breakthroughs***

In patients with ITPA CC genotype, hemoglobin decline was significantly greater and the percentage of patients in whom total RBV dose was <60% of standard and/or treatment was withdrawn was significantly higher compared with CA/AA genotype. However, SVR rates were equivalent between CC and CA/AA genotypes, and within a subset of patients with IL28B (rs8099917) TT genotype, SVR rates tended to be higher in patients with ITPA CC genotype, although the difference was not significant.

***Peer review***

The topic is interesting and relevant. The manuscript is well written and concise.

**REFERENCES**

1 **Enomoto N**, Takada A, Nakao T, Date T. There are two major types of hepatitis C virus in Japan. *Biochem Biophys Res Commun* 1990; **170**: 1021-1025 [PMID: 2117923 DOI: 10.1016/0006-291X(90)90494-8]

2 **Hayashi K**, Fukuda Y, Nakano I, Katano Y, Toyoda H, Yokozaki S, Hayakawa T, Morita K, Nishimura D, Kato K, Urano F, Takamatsu J. Prevalence and characterization of hepatitis C virus genotype 4 in Japanese hepatitis C carriers. *Hepatol Res* 2003; **25**: 409-414 [PMID: 12699851 DOI: 10.1016/S1386-6346(03)00016-0]

3 **Fried MW**, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 2002; **347**: 975-982 [PMID: 12324553 DOI: 10.1056/NEJMoa020047]

4 **Hadziyannis SJ**, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. *Ann Intern Med* 2004; **140**: 346-355 [PMID: 14996676 DOI: 10.7326/0003-4819-140-5-200403020-00010]

5 **Manns MP**, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001; **358**: 958-965 [PMID: 11583749 DOI: 10.1016/S0140-6736(01)06102-5]

6 **Hézode C**, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourlière M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009; **360**: 1839-1850 [PMID: 19403903 DOI: 10.1056/NEJMoa0807650]

7 **McHutchison JG**, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009; **360**: 1827-1838 [PMID: 19403902 DOI: 10.1056/NEJMoa0806104]

8 **Akuta N**, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. *J Med Virol* 2012; **84**: 1097-1105 [PMID: 22585728 DOI: 10.1002/jmv.23262]

9 **Ge D**, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009; **461**: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]

10 **Suppiah V**, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Müller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 2009; **41**: 1100-1104 [PMID: 19749758 DOI: 10.1038/ng.447]

11 **Tanaka Y**, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009; **41**: 1105-1109 [PMID: 19749757 DOI: 10.1038/ng.449]

12 **Kobayashi M**, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Chayama K, Miyakawa Y, Kumada H. Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus. *J Gastroenterol* 2012; **47**: 596-605 [PMID: 22438096 DOI: 10.1007/s00535-012-0531-1]

13 **Watanabe T**, Tanaka Y. IL28B: Drive the hepatitis C treatment setting toward a tailored approach. Nagoya Med J 2011; **52:** 51-56

14 **Fellay J**, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB. *ITPA* gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 2010; **464**: 405-408 [PMID: 20173735 DOI: 10.1038/nature08825]

15 **Arenas M**, Duley J, Sumi S, Sanderson J, Marinaki A. The *ITPA* c.94C& gt; A and g.IVS2+21A& gt; C sequence variants contribute to missplicing of the *ITPA* gene. *Biochim Biophys Acta* 2007; **1772**: 96-102 [PMID: 17113761]

16 **Cao H**, Hegele RA. DNA polymorphisms in *ITPA* including basis of inosine triphosphatase deficiency. *J Hum Genet* 2002; **47**: 620-622 [PMID: 12436200 DOI: 10.1007/s100380200095]

17 **Stepchenkova EI**, Tarakhovskaya ER, Spitler K, Frahm C, Menezes MR, Simone PD, Kolar C, Marky LA, Borgstahl GE, Pavlov YI. Functional study of the P32T *ITPA* variant associated with drug sensitivity in humans. *J Mol Biol* 2009; **392**: 602-613 [PMID: 19631656 DOI: 10.1016/j.jmb.2009.07.051]

18 **Sumi S**, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, Thein SL, Ansari A, Sanderson J, De Abreu RA, Simmonds HA, Duley JA. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. *Hum Genet* 2002; **111**: 360-367 [PMID: 12384777 DOI: 10.1007/s00439-002-0798-z]

19 **Suzuki F**, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, Hosaka T, Kobayashi M, Saito S, Arase Y, Ikeda K, Kobayashi M, Chayama K, Kamatani N, Nakamura Y, Miyakawa Y, Kumada H. Influence of *ITPA* polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. *Hepatology* 2011; **53**: 415-421 [PMID: 21246582 DOI: 10.1002/hep.24058]

20 **Sakamoto N**, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. *ITPA* gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 2010; **40**: 1063-1071 [PMID: 20977565 DOI: 10.1111/j.1872-034X.2010.00741.x]

21 **Ochi H**, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, Tsunoda T, Hayes CN, Kumada H, Nakamura Y, Chayama K. *ITPA* polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. *Gastroenterology* 2010; **139**: 1190-1197 [PMID: 20637204 DOI: 10.1053/j.gastro.2010.06.071]

22 **Azakami T**, Hayes CN, Sezaki H, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Tsuge M, Imamura M, Kawakami Y, Takahashi S, Ochi H, Nakamura Y, Kamatani N, Chayama K. Common genetic polymorphism of *ITPA* gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy. *J Med Virol* 2011; **83**: 1048-1057 [PMID: 21503919 DOI: 10.1002/jmv.22069]

23 **Osinusi A**, Naggie S, Poonia S, Trippler M, Hu Z, Funk E, Schlaak J, Fishbein D, Masur H, Polis M, Kottilil S. *ITPA* gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. *J Med Virol* 2012; **84**: 1106-1114 [PMID: 22585729 DOI: 10.1002/jmv.23302]

24 **De Franceschi L**, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, Stanzial AM, Solero P, Corrocher R. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. *Hepatology* 2000; **31**: 997-1004 [PMID: 10733558 DOI: 10.1053/he.2000.5789]

25 **Russmann S**, Grattagliano I, Portincasa P, Palmieri VO, Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. *Curr Med Chem* 2006; **13**: 3351-3357 [PMID: 17168855 DOI: 10.2174/092986706778773059]

26 **Hitomi Y**, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, Shianna KV, Urban TJ, Goldstein DB. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. *Gastroenterology* 2011; **140**: 1314-1321 [PMID: 21199653 DOI: 10.1053/j.gastro.2010.12.038]

27 **Tanaka Y**, Kurosaki M, Nishida N, Sugiyama M, Matsuura K, Sakamoto N, Enomoto N, Yatsuhashi H, Nishiguchi S, Hino K, Hige S, Itoh Y, Tanaka E, Mochida S, Honda M, Hiasa Y, Koike A, Sugauchi F, Kaneko S, Izumi N, Tokunaga K, Mizokami M. Genome-wide association study identified *ITPA*/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. *Hum Mol Genet* 2011; **20**: 3507-3516 [PMID: 21659334 DOI: 10.1093/hmg/ddr249]

28 **Thompson AJ**, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, Urban TJ, Shianna KV, Muir AJ, Fried MW, Afdhal NH, Goldstein DB, McHutchison JG. Variants in the *ITPA* gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. *Gastroenterology* 2010; **139**: 1181-1189 [PMID: 20547162 DOI: 10.1053/j.gastro.2010.06.016]

29 **Thompson AJ**, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. *Hepatology* 2011; **53**: 389-395 [PMID: 21274861 DOI: 10.1002/hep.24068]

30 **Eskesen AN**, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O. Genetic variants at the *ITPA* locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. *Eur J Gastroenterol Hepatol* 2012; **24**: 890-896 [PMID: 22584257 DOI: 10.1097/MEG.0b013e3283546efd]

31 **Doyle JS**, Hellard ME, Thompson AJ. The role of viral and host genetics in natural history and treatment of chronic HCV infection. *Best Pract Res Clin Gastroenterol* 2012; **26**: 413-427 [PMID: 23199501 DOI: 10.1016/j.bpg.2012.09.004]

**P-Reviewers** Chamulitrat W, Müller T, Swierczynski JT **S-Editor** Wen LL  **L-Editor**  **E-Editor**

**Figure 1 Chronological variation of hemoglobin levels (A) and platelet counts (B) in each inosine triphosphatase genotype at rs1127354.** a*P* < 0.05, b*P* < 0.01 compared with CA/AA groups.

**Table 1** **Baseline characteristics of patients**

*ITPA*: Inosine triphosphatase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein; NS: Not significant.

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

NS

Age (yr)

Gender: Male/Female

HCV RNA (log IU/mL)

Hemoglobin (g/dL)

WBC (x103/μL)

Platelet (x104/μL)

AST (IU/L)

ALT (IU/L)

GGT (IU/L)

AFP (ng/mL)

Staging: F1,2/F3,4

IL28B: TT/TG+GG

59 ± 11

37/46

5.9 ± 0.5

13.8 ± 1.7

5.0 ± 1.5

18.0 ± 7.0

58.2 ± 42.3

68.4 ± 56.8

55.3 ± 49.4

24.2 ± 61.8

49/27

53/30

61 ± 8

18/19

6.2 ± 0.6

13.4 ± 1.5

4.7 ± 1.2

18.0 ± 6.0

56.8 ± 34.9

65.5 ± 40.0

56.1 ± 52.3

5.3 ± 4.0

19/16

29/8

***ITPA* polymorphism (rs1127354)**

***P* value**

**CC (*n* = 83)**

**CA/AA (*n* = 37)**

**Table 2** **Sustained virological response rates according to total ribavirin dose in each inosine triphosphatase genotype**

Each group includes patients in whom treatment was withdrawn. SVR: Sustained virological response; RBV: Ribavirin; *ITPA*: Inosine triphosphatase.

***ITPA* genotype**

**(rs1127354)**

CA + AA (*n*=37)

CC (*n*=83)

**Total**

40.5% (15/37)

44.6% (37/83)

**Patients with**

**<60% total RBV dose**

12.5% (1/8)

20.0% (6/30)

48.3% (14/29)

58.5% (31/53)

**Patients with**

**>60% total RBV dose**

**Table 3 Virological response according to classification by inosine triphosphatase and interleukin 28B single-nucleotide polymorphisms**

SVR: Sustained virological response; RVR: Rapid virological response; EVR: Early virological response; *ITPA*: Inosine triphosphatase; *IL28B*: Interleukin 28B.

10.3% (3/29)

62.1% (18/29)

44.8% (13/29)

18.9% (10/53)

66.0% (35/53)

54.7% (29/53)

RVR

RVR + EVR

SVR

13.3% (4/30)

26.6% (8/30)

26.6% (8/30)

0% (0/8)

12.5% (1/8)

25.0% (2/8)

***IL28B*: TG + GG**

***IL28B*: TT**

**CA + AA (*n*=8)**

**CC (*n*=53)**

**Virological response**

***ITPA*:**

**CA + AA (*n*=29)**

**CC (*n*=30)**

**Table 4 Comparison of profile between sustained virological response and non-** **sustained virological response patients**

1% of RBV administration to the scheduled total dose of full-length treatment (48 or 72 wk). SVR: Sustained virological response; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; GGT: γ-glutamyl transpeptidase; AFP: α-fetoprotein; *ITPA*: inosine triphosphatase; NS: Not significant.

Age (yr)

Gender: male/female

Body mass index (kg/m2)

HCV RNA (log IU/mL)

Hemoglobin (g/dL)

WBC （x103/mL）

Platelet（x104/mL）

AST (IU/L)

ALT (IU/L)

GGT (IU/L)

AFP (ng/mL)

Staging: F1,2/F3,4

72 week treatment: +/–

Ribavirin dose (%)1

*ITPA*: CC/CA+AA

*IL28B*: TT/TG+GG

**Factors**

**non-SVR (*n*=66)**

61 ± 9

33/33

22.6 ± 3.3

6.1 ± 0.6

13.8 ± 1.8

5.1 ± 1.5

17 ± 6

66.7 ± 47.1

75.1 ± 61.1

67.4 ± 61.2

10.1 ± 24.2

28/30

14/52

76 ± 41

45/21

38/28

**SVR (*n*=54)**

57 ± 12

21/33

23.5 ± 4.1

5.9 ± 0.6

13.7 ± 1.3

4.7 ± 1.3

20 ± 7

46.2 ± 25.8

56.1 ± 33.3

39.8 ± 24.1

8.3 ± 19.8

40/12

10/44

90 ± 35

38/16

44/10

*P* <0.05

NS

NS

*P* <0.05

NS

NS

*P* <0.05

NS

NS

NS

NS

*P* <0.01

NS

NS

NS

*P* <0.01

***P* value**

**Table 5 Multivariate analysis for predictive factors associated with SVR**

*IL28B*: Interleukin 28B.

HCV RNA (log IU/mL)

*IL28B* (rs8099917)

***P* value**

0.008

0.023

1.42‒10.95

1.18‒10.10

**95%CI**

**Category**

1. ≥ 6.0: 1.0

2. < 6.0: 3.94

1. TG + GG: 1.0

2. TT: 3.46

**Factors**